NCT03994510 SHame prOpensity in bOrderline Personality Disorder
| NCT ID | NCT03994510 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Montpellier |
| Condition | Borderline Personality Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 688 participants |
| Start Date | 2020-09-18 |
| Primary Completion | 2031-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 688 participants in total. It began in 2020-09-18 with a primary completion date of 2031-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Borderline Personality Disorder (BPD) is a common psychiatric disorder occurring in 2 to 6% of the population. 70% of patients with BPD do at least one Suicide Attempt (SA) in their lives. It makes BPD the most related to SA condition. Negative interpersonal events are among the main stressor inducing a SA. Patients with BPD are characterized by emotional dysregulation, impulsivity (repeated parasuicidal and suicidal behaviors), and instability in interpersonal relationships. The feeling of shame related to this psychiatric disorder could be one of the causes of the high SA rate. In this study, patients with BPD will be follow-up during 5 years. The main objective is to study the propensity to feel shame as a predictor of SA. This include: * Study of shame propensity as a predictive factor of suicidal behavior - Identify homogeneous subgroups of patients with BPD based on SA, and overall functioning. * Identify biological markers predicting SA * Identify predictive and protective treatments (pharmacological and psychotherapeutic) for SA
Eligibility Criteria
Inclusion criteria: * To be over 18 * Clinical diagnosis of BPD using the SCID II (Structured Clinical Interview for DSM-IV-Text Reviewed Axis II Personality Disorders) * Having signed the informed consent * Able to understand the nature, the purpose and the methodology of the study * Able to understand and perform the clinical evaluations Exclusion criteria: * Deprived of liberty (by judicial or administrative decision) * Protected by law (guardianship) * Exclusion period in relation to another protocol * Not affiliated to a social security scheme
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03994510 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Borderline Personality Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03994510 currently recruiting?
Yes, NCT03994510 is actively recruiting participants. Contact the research team at d-ducasse@chu-montpellier.fr for enrollment information.
Where is the NCT03994510 trial being conducted?
This trial is being conducted at Montpellier, France.
Who is sponsoring the NCT03994510 clinical trial?
NCT03994510 is sponsored by University Hospital, Montpellier. The trial plans to enroll 688 participants.